Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability
Myriad Genetics reported Q2 2026 revenues of $190.7 million, an 11% decline year-over-year driven by a slight volume decrease and reduced revenue per test. The company launched new cancer diagnostics products and expanded test availability, particularly in the Cancer Care Continuum segment, while executing initiatives to improve reimbursement predi…